Search General Info
Search Education
Search Partnering Companies
“The microbiome” is everywhere in the press and fast-increasing resources are devoted to it in labs worldwide. Biotechs are busy getting microbiome-modifying compounds of all kinds to the clinic while academics generate eye-watering amounts of genomic and metabolomic data.
But when will drugs and other products come out of all those efforts? The number of key phase Ib and phase II read-outs will reach an inflexion point in 2020, will pharma and the investor community adopt those projects more widely? And in the transition from lab to clinic to drug-on-market, can this new frontier learn from those who have gone before? Panelists will address these questions and more.
But when will drugs and other products come out of all those efforts? The number of key phase Ib and phase II read-outs will reach an inflexion point in 2020, will pharma and the investor community adopt those projects more widely? And in the transition from lab to clinic to drug-on-market, can this new frontier learn from those who have gone before? Panelists will address these questions and more.
Moderator
Speakers
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
